217 related articles for article (PubMed ID: 38143235)
1. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
3. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.
Song G; Shi Y; Meng L; Ma J; Huang S; Zhang J; Wu Y; Li J; Lin Y; Yang S; Rao D; Cheng Y; Lin J; Ji S; Liu Y; Jiang S; Wang X; Zhang S; Ke A; Wang X; Cao Y; Ji Y; Zhou J; Fan J; Zhang X; Xi R; Gao Q
Nat Commun; 2022 Mar; 13(1):1642. PubMed ID: 35347134
[TBL] [Abstract][Full Text] [Related]
6. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
7. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
[TBL] [Abstract][Full Text] [Related]
8. Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma.
Xuan Z; Liu L; Zhang G; Zheng X; Jiang J; Wang K; Huang P
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130420. PubMed ID: 37433400
[TBL] [Abstract][Full Text] [Related]
9. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
10. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.
Ahn KS; O'Brien D; Kang YN; Mounajjed T; Kim YH; Kim TS; Kocher JA; Allotey LK; Borad MJ; Roberts LR; Kang KJ
Hepatol Int; 2019 Jul; 13(4):490-500. PubMed ID: 31214875
[TBL] [Abstract][Full Text] [Related]
11. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
[TBL] [Abstract][Full Text] [Related]
14. Dense GM-CSFR
Saranaruk P; Waraasawapati S; Chamgramol Y; Sawanyawisuth K; Paungpan N; Somphud N; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
PeerJ; 2023; 11():e14883. PubMed ID: 36883059
[TBL] [Abstract][Full Text] [Related]
15. Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis.
Bao X; Li Q; Chen J; Chen D; Ye C; Dai X; Wang Y; Li X; Rong X; Cheng F; Jiang M; Zhu Z; Ding Y; Sun R; Liu C; Huang L; Jin Y; Li B; Lu J; Wu W; Guo Y; Fu W; Langley SR; Tano V; Fang W; Guo T; Sheng J; Zhao P; Ruan J
Cancer Immunol Res; 2022 Jul; 10(7):811-828. PubMed ID: 35604302
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
17. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.
Sang C; Yan L; Lin J; Lin Y; Gao Q; Shen X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):199. PubMed ID: 38627278
[TBL] [Abstract][Full Text] [Related]
20. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
